Laboratory of Pathology, School of Veterinary Medicine, Aristotle University of Thessaloniki, Thessaloniki 541 24, Greece.
Vet Res Commun. 2009 Dec;33(8):905-19. doi: 10.1007/s11259-009-9308-2.
The objective of the study was to determine the immunohistochemical expression of canine TERT in canine testicular tumours comparing two different antibodies for TERT, and to correlate them with well established markers specific to dividing cells such as PCNA and ki67, and with expression of the p53 tumour suppressor gene. The study included 36 cases of canine testicular tumours, which were categorized as 12 Sertoli Cell Tumours (SCT), 20 seminomas, 3 interstitial cell tumours and 1 mixed germ cell-sex cord stromal tumour (MT). Two antibodies for hTERT were examined; a highly specific TERT antibody, RCK-hTERT, was evaluated for the first time. Immunodetection of RCK-hTERT was observed in 31% of tumours examined (6/20 Seminomas, 4/12 SCT, 1/3 interstitial cell tumour and 0/1 mixed germ cell-sex cord stromal tumour), while the NCL-hTERT in 67% of them (15/20 Seminomas, 6/12 SCT, 3/3 interstitial cell tumour and 0/1 ΜΤ). PCNA immunoreactivity was detected in all cases. Regarding ki67, 3 SCT, 12 seminomas and all interstitial cell tumours showed clear immunoreaction. p53 immunoreactivity was detected in 6 SCT, 15 seminomas and all interstitial cell tumours. The immunohistochemical expression of both TERT antibodies are discussed and compared in order to clarify their potential usefulness in canine testicular malignancies in relation to the expression of well known cell cycle markers. Our results indicate that TERT and PCNA are useful proliferation markers but not helpful to evaluate prognosis. Instead of that ki67 and p53 could be used for predicting aggressiveness in this group of tumours.
本研究的目的是确定犬睾丸肿瘤中 TERT 的免疫组织化学表达,比较两种不同的 TERT 抗体,并将其与已知的细胞分裂标志物如 PCNA 和 ki67 以及 p53 肿瘤抑制基因的表达进行相关性分析。本研究包括 36 例犬睾丸肿瘤,分为 12 例支持细胞瘤(SCT)、20 例精原细胞瘤、3 例间质细胞瘤和 1 例混合性生殖细胞-性索基质肿瘤(MT)。检测了两种 hTERT 抗体;首次评估了一种高度特异性的 TERT 抗体 RCK-hTERT。在检测的肿瘤中,RCK-hTERT 的免疫检测率为 31%(6/20 例精原细胞瘤、4/12 例 SCT、1/3 例间质细胞瘤和 0/1 例混合性生殖细胞-性索基质肿瘤),而 NCL-hTERT 的免疫检测率为 67%(15/20 例精原细胞瘤、6/12 例 SCT、3/3 例间质细胞瘤和 0/1 例 MT)。所有病例均检测到 PCNA 免疫反应。关于 ki67,3 例 SCT、12 例精原细胞瘤和所有间质细胞瘤均显示明显的免疫反应。6 例 SCT、15 例精原细胞瘤和所有间质细胞瘤均检测到 p53 免疫反应。讨论并比较了两种 TERT 抗体的免疫组织化学表达,以阐明它们在犬睾丸恶性肿瘤中与已知细胞周期标志物表达的潜在有用性。我们的结果表明,TERT 和 PCNA 是有用的增殖标志物,但不能用于评估预后。相反,ki67 和 p53 可用于预测该组肿瘤的侵袭性。